These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 22111776)

  • 21. Clinical trials of new anticoagulants.
    Anderson J; O'Donnell M
    Vnitr Lek; 2006 Mar; 52 Suppl 1():123-6. PubMed ID: 16637460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Old and new anticoagulant drugs: a minireview.
    Mannucci PM; Franchini M
    Ann Med; 2011 Mar; 43(2):116-23. PubMed ID: 21254900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral thromboprophylaxis following total hip or knee replacement: review and multicentre experience with dabigatran etexilate.
    Kendoff D; Perka C; Fritsche HM; Gehrke T; Hube R
    Open Orthop J; 2011; 5():395-9. PubMed ID: 22276081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful hemostasis and reversal of highly elevated PT/INR after dabigatran etexilate use in a patient with acute kidney injury.
    Jones JM; Ryan HM; Tieszen M; Leedahl DD
    Am J Emerg Med; 2016 Apr; 34(4):758.e5-6. PubMed ID: 26324007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The discovery of dabigatran etexilate.
    van Ryn J; Goss A; Hauel N; Wienen W; Priepke H; Nar H; Clemens A
    Front Pharmacol; 2013; 4():12. PubMed ID: 23408233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carbon-13 and carbon-14 labeled dabigatran etexilate and tritium labeled dabigatran.
    Latli B; Kiesling R; Aßfalg S; Chevliakov M; Hrapchak M; Campbell S; Gonnella N; Busacca CA; Senanayake CH
    J Labelled Comp Radiopharm; 2016 Dec; 59(14):648-656. PubMed ID: 27146196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse events in patients initiated on dabigatran etexilate therapy in a pharmacist-managed anticoagulation clinic.
    Donaldson M; Norbeck AO
    Pharm Pract (Granada); 2013 Apr; 11(2):90-5. PubMed ID: 24155855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate.
    Bellamy L; Rosencher N; Eriksson B
    Patient Prefer Adherence; 2009 Nov; 3():173-7. PubMed ID: 19936159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What neurosurgeons need to know about dabigatran etexilate (pradax(®)/pradaxa(®)/prazaxa(®)).
    Dwyer CM; Damodaran O; Heckelmann M; Sheridan MM
    Asian J Neurosurg; 2015; 10(2):66-8. PubMed ID: 25972932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Cost-Effectiveness Of Dabigatran Etexilate Compared With Warfarin In The Treatment And Secondary Prevention Of Acute Venous Thromboembolism In The Uk.
    Jugrin AV; Ustyugova AV; Urbich M; Lamotte M; Sunderland TJ
    Value Health; 2014 Nov; 17(7):A489. PubMed ID: 27201451
    [No Abstract]   [Full Text] [Related]  

  • 31. The Cost-Effectiveness Of Dabigatran Etexilate Compared With Rivaroxaban In The Treatment Of Acute Venous Thromboembolism In The Uk.
    Jugrin AV; Ustyugova AV; Urbich M; Lamotte M; Sunderland TJ
    Value Health; 2014 Nov; 17(7):A489. PubMed ID: 27201449
    [No Abstract]   [Full Text] [Related]  

  • 32. Dabigatran etexilate shows at least similar effect compared with enoxaparin in prevention of embolic thromboembolism following total hip arthroplasty: (RENOVATE 2 trial).
    Vintila V
    Maedica (Bucur); 2010 Apr; 5(2):153. PubMed ID: 21977147
    [No Abstract]   [Full Text] [Related]  

  • 33. Monitoring the distribution of warfarin in blood plasma.
    Rosengren AM; Karlsson BC; Nicholls IA
    ACS Med Chem Lett; 2012 Aug; 3(8):650-2. PubMed ID: 24900525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brandão LR, Albisetti M, Halton J, et al; DIVERSITY Study Investigators. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood. 2020;135(7):491-504.
    Blood; 2020 May; 135(19):1720. PubMed ID: 32379879
    [No Abstract]   [Full Text] [Related]  

  • 35. Dabigatran was noninferior to warfarin for preventing recurrent venous thromboembolism.
    Gandara E
    Ann Intern Med; 2010 Apr; 152(8):JC4-7. PubMed ID: 20404376
    [No Abstract]   [Full Text] [Related]  

  • 36. Advances in oral anticoagulants: focus on dabigatran etexilate.
    Hazlewood KA; Weiland CM
    Expert Rev Clin Pharmacol; 2010 Nov; 3(6):727-37. PubMed ID: 22111776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
    Baetz BE; Spinler SA
    Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dabigatran etexilate: the first oral anticoagulant available in the United States since warfarin.
    Tran A; Cheng-Lai A
    Cardiol Rev; 2011; 19(3):154-61. PubMed ID: 21464643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.
    Acharjee S; Cannon CP
    Crit Pathw Cardiol; 2011 Jun; 10(2):84-6. PubMed ID: 21988948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical studies, the interests and limits of using dabigatran in atrial fibrillation].
    Sternotte A; Douxfils J; Chatelain B; Chatelain C; Mullier F; Dogné JM; Spinewine A
    J Pharm Belg; 2012 Mar; (1):8-17. PubMed ID: 22536678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.